+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 18Years +
All Genders
ID07592273

Evaluating Surabgene Lomparvovec Gene Therapy via Suprachoroidal Injection for Adults with Diabetic Retinopathy Without Center-Involved Macular Edema in a Randomized, Controlled Study

Led by AbbVie · Updated on 2026-10-29

576

Participants Needed

40

Research Sites

395 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying diabetic retinopathy DR, an eye condition caused by diabetes that damages blood vessels in the retina and can lead to vision loss. This trial evaluates surabgene lomparvovec sura-vec, a gene therapy given as a one-time injection into the suprachoroidal space SCS, aiming to treat non-proliferative DR without center-involved diabetic macular edema CI-DME and prevent vision-threatening events. The study includes Phase 2b, Phase 3, and a bilateral treatment portion with about 576 adult participants across the United States and Puerto Rico. Participants are randomly assigned to receive sura-vec plus prophylactic steroids or sham injections plus artificial tears in one eye during the Phase 2b and Phase 3 portions. Those receiving sham may later cross over to sura-vec treatment. In the bilateral portion, participants receive sura-vec and steroids in both eyes. Each participant receives a single injection per eye. Follow-up continues for up to five years after treatment to monitor outcomes and safety. Throughout the study, participants attend regular clinic visits for medical assessments, blood tests, and questionnaires to monitor the treatments effects and any side effects. Researchers will track diabetic retinopathy severity using the Diabetic Retinopathy Severity Scale DRSS and watch for vision-threatening events. Safety is closely monitored, including eye inflammation and other adverse events, with follow-up extending up to approximately two years for the bilateral portion and five years overall. Participants should expect a higher treatment burden than standard care.

CONDITIONS

Brief Title

Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema

Research Team

A

ABBVIE CALL CENTER

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here